The NASEM report, which was commissioned by the FDA, gives an update on current research in the pain field.
Patients suffering from postherpetic nearalgia found relief taking gabapentin.
An FDA panel previously voted that the drug's benefits no longer outweigh its risks.
Previous research has suggested a link between early use of pregabalin in pregnancy and congenital malformations.
While adherence was improved, health care costs were increased.
A 10-minute application resulted in significant reductions in pain scores.
The patch used in the study is approved in the United States for postherpetic neuralgia and in Europe for PNP arising from any etiology.
Even minor improvements in fibromyalgia symptoms, depression, anxiety, and pain can have a significant impact on the quality of life in patients with fibromyalgia.
Reports of pain may indicate a preclinical course of amyotrophic lateral sclerosis.
As the population ages, and as both the incidence of diabetes and the survival rates after chemotherapy treatment increase, the number of patients with neuropathic pain is expected to rise.
The VA and DoD issue a clinical practice guideline regarding opioid therapy for chronic pain in veterans.
Avoidance can lead to headache disability by reducing pain thresholds and preventing pain habituation.
The characteristics of migraine may change throughout a woman's reproductive stages, and may require different treatment strategies.
No significant between-group differences were observed for change in leg pain intensity and disability.
Clinically and statistically significant reductions in peripheral neuropathy were seen following neurofeedback.
Spinal cord stimulation using precision approach via 3D neural targeting shows superior efficacy in treating chronic axial low back pain compared with a trial-and-error method to achieve desired paresthesia.
Remote electrical stimulation appears to have similar efficacy to standard drug treatments, including triptans.
A significant decrease in migraine frequency was observed, but it is not clear how large a role placebo effect plays in treatment response.
Future research should focus on whether cogniphobia can be a modifiable factor in the treatment of patients with migraine.
The recommendations promote the use of hot compresses and physical therapy as first-line treatment of low back pain.
New research suggests that opioid addiction may be linked to a genetic variant, and more personalized treatment may help those with the change.
Interventions with clinical massage or guided imagery may help ease pain and anxiety in patients in a progressive care unit.
The abuse of opioids or other substances may cause short-term amnesia.
Effectively treating pain may help improve cognitive and functional outcomes in patients with depression.
The new guidelines offer guidance on dosing, including reduced starting and maintenance dosing and safety precautions for diagnosing and treating complications.
The FDA instituted widespread updates to product labeling for opioid medications in December, 2016.
While likely a placebo effect, spinal manipulation may be an option for patients with migraine refractory to treatment.
Rates of severe pain were significantly higher in veterans with back and jaw pain, severe headaches or migraine, and neck pain.
The US FDA is requiring that label changes be made to reflect the risks involved with extended exposure to anesthetics and sedatives in children and pregnant women.
Recent findings offer a new avenue for the development of peripheral analgesics with minimal adverse effects.
Neurology Advisor Articles
- Minocycline May Slow Progression From Clinically Isolated Syndrome to Multiple Sclerosis
- Brain Inflammation Observed in Obsessive-Compulsive Disorder
- Extended-Release Amantadine Reduces Levodopa-Induced Dyskinesia in Parkinson's Disease
- Growing Old Without Alzheimer's Pathology: What's the Secret?
- Traumatic Brain Injury May Increase Later Risk of Dementia